1674 – Dostarlimab in mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer

Page last updated: 13 May 2021

Application Detail

Description of Medical Service

Immunohistochemistry (IHC) testing for identification of mismatch repair deficiency for eligibility to access dostarlimab on the PBS in patients with recurrent or advanced endometrial cancer.

Description of Medical Condition

Patients with recurrent or advanced endometrial cancer which are mismatch repair deficient, who have progressed following prior treatment.

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1360 KB)
Application Form (Word 298 KB)

Consultation Survey

Consultation Survey (PDF 584 KB)
Consultation Survey (Word 68 KB)

PICO Confirmation


Assessment Report


Public Summary Document


Meetings for this Application